A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of LB03002, a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy with Genotropin in Treatment Naive Children with Growth Failure due to Insufficient Secretion of Endogenous Growth Hormone
| DEC-NET Serial number IT558 | |
| Published online | 20/04/2006 14.12.00 |
| Last updated | 11/08/2006 16.04.07 |
| Other protocol ID number | BPLG-004 |
| Current trial status | Open (actively recruiting new participants) |
| Major Disease (ICD9 class) | Disorders of the pituitary gland and its hypothala |
| Experimental drug | |
| SOMATROPIN | |
| Gender | 0 |
| Age (range) | |
Eligibility criteria | |
Trial design/methodology | |
| Phase | 3 |
| Kind of study | Efficacy Safety |
| Design | Controlled |
| Promoter |
| BIOPARTNERS GMBH (Industry) |
| ISRCTN | EudraCT 2005-000346-36 |
